MarketPulse

AMT-130

10 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Hagens Berman

Gene Therapy Firm uniQure Faces Securities Lawsuit Over Alleged FDA Data Distortion

Hagens Berman investigates $QURE for misrepresenting FDA interactions on gene therapy AMT-130. Stock crashed 49% after FDA publicly rebuked company's data claims.
QUREinvestor lossessecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Claimsfiler

uniQure Stock Crashes 49% on FDA Setback; Class Action Deadline Looms

uniQure faces securities lawsuit after FDA rejected AMT-130 approval pathway. Stock plummeted 49% following disclosure. Lead plaintiff deadline: April 13, 2026.
QUREsecurities class actionlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··Claimsfiler

Gene Therapy Stock $QURE Crashes 49% as FDA Rejects AMT-130 Data; Class Action Looms

$QURE plunged 49% after FDA rejected AMT-130 Phase I/II data for accelerated approval. Securities lawsuit filed; lead plaintiff deadline April 13, 2026.
QUREsecurities class actionlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··Kahn Swick & Foti, Llc

uniQure Stock Crashes 49% After FDA Rejects Gene Therapy Data

uniQure stock plunges 49% after FDA rejects gene therapy data for AMT-130, triggering securities fraud class action lawsuit for investors trading September-October 2025.
QUREsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Claimsfiler

uniQure Class Action: Deadline Set for Lead Plaintiff Claims Over FDA Disclosure

uniQure faces class action lawsuit over failing to disclose FDA rejection of AMT-130 drug candidate, causing 49% stock decline. Lead plaintiff deadline: April 13, 2026.
QUREsecurities class actionlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··Kirby Mcinerney Llp

Class Action Lawsuit Alleges uniQure Withheld FDA Study Design Concerns

Class action lawsuit alleges uniQure withheld FDA study design concerns from investors, causing 49% stock decline after disclosure in November 2025.
QUREsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Claimsfiler

uniQure Faces Securities Lawsuit Over FDA Disclosure Gap; Lead Plaintiff Deadline Set

uniQure faces securities lawsuit over failing to disclose that FDA rejected its gene therapy candidate AMT-130, causing stock to plunge 49%. Lead plaintiff deadline set for April 13, 2026.
QUREsecurities class actionlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··Kahn Swick & Foti, Llc

uniQure Stock Drops 49% Following FDA Rejection of AMT-130 Accelerated Approval

uniQure stock plummeted 49% after FDA rejected accelerated approval for gene therapy AMT-130, triggering a class action lawsuit alleging securities fraud.
QUREsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Robbins Llp

uniQure Investors Face April Deadline in Securities Class Action Over FDA Disclosure Claims

Securities lawsuit against uniQure alleges misleading FDA disclosure statements about gene therapy candidate AMT-130. Stock fell 49% after November FDA feedback; investors must file claims by April 13, 2026.
QUREclass action lawsuitshareholder fraud
GlobeNewswire Inc.GlobeNewswire Inc.··Faruqi & Faruqi, Llp

QURE Investors Face April Deadline in Securities Class Action Over AMT-130 Claims

uniQure faces securities lawsuit alleging misleading statements about AMT-130's FDA pathway. Stock dropped 49% after FDA reversed stance. Investors have April deadline for lead plaintiff claims.
QUREsecurities class actionmisleading statements